*79 bln pound deal would be biggest takeover of UK company. LONDON/ BRUSSELS, July 29- The board of brewer SABMiller will recommend its shareholders approve a sweetened takeover offer by Anheuser-Busch InBev, the company said on Friday, capping a week of high drama about the fate of the consumer industry's biggest-ever merger. Its earlier offer had been made less... » Read More
FMHR trader Pete Najarian takes a close look at unusual activity in options for Hillshire Brands, and the action in its stock as takeover talks continue.
Pilgrim's Pride is sweetening its takeover offer for Hillshire Brands. CNBC's Jim Cramer and David Faber discuss the "insane" bidding for Hillshire.
Mario Gabelli, Gamco Investors chairman & CEO, shares his thoughts on how to play the social media, e-commerce, and natural gas space.
Mario Gabelli, Gamco Investors chairman & CEO, explains why he is watching shares of Protective Life, Interpublic Group, and Hillshire Brands.
Tyson Foods is jumping in the takeover battle for Hillshire. The "Squawk on the Street" news team discuss Tyson's $50 a share offer.
This year has been the year of mergers, acquisitions and hostile takeovers. Attorney Frank Aquila, Sullivan & Cromwell, discusses what's behind the recent M&A boom.
The "Squawk on the Street" take a close look at the offer from Pilgrim's Pride for Hillshire Brands. Pilgrim's Pride wants Hillshire to drop Pinnacle Foods of which Birds Eye Foods is a brand.
CNBC's David Faber and Jim Cramer discuss the latest M&A action, including Valeant Pharmaceuticals raising its takeover bid for Allergan, and GE improving its offer for France's Alstom.
CNBC's Dominic Chu reports Hillshire Brands has responded to the proposal by Pilgrim's Pride to acquire Hillshire for about $6.4 billion
The "Squawk on the Street" news team discusses the report that Pilgrim's Pride is offering to acquire Hillshire Brands for $6.4 billion.
Don't start your trading day without finding out what CNBC's Jim Cramer is watching ahead of the opening bell. Today Cramer shares his thoughts on Pilgrim Pride's bid for Hillshire Brands.
John Eade, Argus Research, discusses Pfizer's likely next move after abandoning its attempt to buy AstraZeneca. There's a good chance AstraZeneca management could ask Pfizer to come back to the table, says Eade.
$117 billion was not enough for AstraZeneca. CNBC's Meg Tirrell looks at Pfizer and AstraZeneca's stocks.
CNBC's Herb Greenberg plays a game of "deal or no deal" and rounds up potential next takeover targets.
CNBC's David Faber reports Hillshire Brands is buying Pinnacle Foods. And Faber comments on Allergan's rejection of Valeant's takeover bid.
Allergan has rejected a $47 billion takeover bid by Valeant Pharmaceuticals. The "Squawk on the Street" news team discuss m&a in pharmaceuticals and the IPO market.
Bill Ackman, Pershing Square Capital Management, explains what led him to reach out to activist investor Carl Icahn. Ackman calls him "a charming guy."
Bill Ackman, Pershing Square Capital Management, weighs in on the Valeant and Allergan controversy and long-term shareholder activism.
CNBC's Scott Wapner speaks to Bill Ackman, Pershing Square Capital Management, about the "winding down" of the old version of Fannie and Freddie and discusses the importance of reform to their programs.
AstraZeneca has rejected Pfizer's sweetened bid claiming it undervalues the company. The "Squawk on the Street" news team shares their thoughts on the latest bid and the U.S. tax code.